RH Q1 Earnings Call: Tariff Disruptions and Global Expansion Define Outlook
Luxury furniture retailer RH (NYSE:RH) missed Wall Street's revenue expectations in Q1 CY2025, but sales rose 12% year on year to $814 million. Next quarter's revenue guidance of $904.3 million underwhelmed, coming in 0.7% below analysts' estimates. Its non-GAAP profit of $0.13 per share was significantly above analysts' consensus estimates.
Is now the time to buy RH? Find out in our full research report (it's free).
Revenue: $814 million vs analyst estimates of $819 million (12% year-on-year growth, 0.6% miss)
Adjusted EPS: $0.13 vs analyst estimates of -$0.07 (significant beat)
Adjusted EBITDA: $106.4 million vs analyst estimates of $104.4 million (13.1% margin, 2% beat)
Revenue Guidance for Q2 CY2025 is $904.3 million at the midpoint, below analyst estimates of $910.9 million
Operating Margin: 6.9%, in line with the same quarter last year
Locations: 125 at quarter end, down from 126 in the same quarter last year
Same-Store Sales rose 7.8% year on year (-3.7% in the same quarter last year)
Market Capitalization: $3.31 billion
RH's first quarter results reflected the impact of ongoing macroeconomic headwinds and management's continued focus on brand elevation and market share gains. CEO Gary Friedman highlighted that, despite operating in what he described as 'the worst housing market in almost fifty years,' RH delivered double-digit sales growth, driven by investments in new product collections, immersive gallery experiences, and the company's ability to capture demand in key global markets. Notably, management pointed to strong performance in its European galleries, particularly RH England, where demand trends surpassed internal benchmarks. Friedman acknowledged the strategic decision to pursue aggressive market share during a downturn, emphasizing, 'We are performing at a level most would expect in a robust housing market.'
Looking ahead, RH's guidance reflects both optimism about international expansion and caution around near-term volatility tied to tariffs and macroeconomic uncertainty. Management expects the opening of flagship galleries in Paris, London, and Milan to serve as significant growth catalysts, with Friedman stating that these locations present 'a multibillion-dollar opportunity' for the brand. However, leadership noted that the recent introduction of new tariffs and associated supply chain disruptions have prompted a temporary delay in key product launches and are expected to impact revenue timing for the next quarter. CFO Jack Preston indicated that, while the company maintains its full-year margin targets, elevated investment in international markets and ongoing tariff negotiations may create further earnings variability through the remainder of the year.
Management attributed quarterly performance to a mix of strong demand in Europe, ongoing product transformation, and tactical responses to trade disruptions, while emphasizing strategic flexibility amid external volatility.
European momentum: RH's galleries in England, Munich, and Dusseldorf saw notable demand growth, with RH England's gallery and online channels up 47% and 44% respectively. Success in these markets encouraged confidence in the brand's disruptive potential across Europe as new flagship locations prepare to open.
Product transformation: Management highlighted the rollout of 18 new collections—including a new Japandi design aesthetic blending Japanese and Scandinavian influences—and ongoing efforts to elevate the product assortment. These initiatives are designed to differentiate RH from competitors and support margin resilience.
Membership discount strategy: In response to heightened industry promotions and a compressed outdoor selling season, RH increased its membership discount from 25% to 30%, and briefly to 35% for select outdoor products. Management described this as a strategic, long-term move to capture market share, rather than a temporary measure.
Tariff mitigation efforts: The company accelerated its shift away from Chinese sourcing, aiming to reduce receipts from China to just 2% by year-end. RH also increased U.S. and Italian production for key upholstery lines, seeking to offset uncertainty from evolving trade policies.
Capital allocation and real estate flexibility: RH continues to hold significant real estate assets, with plans to monetize properties opportunistically. Management cited a portfolio of owned and joint-venture galleries, particularly in Aspen and major U.S. markets, providing both liquidity options and strategic growth opportunities.
RH's outlook is shaped by the pace of international expansion, margin management through product and sourcing shifts, and the evolving tariff landscape.
International gallery expansion: Management expects the upcoming openings of flagship locations in Paris, London, and Milan to meaningfully expand RH's global reach. These galleries are positioned in high-visibility, luxury retail districts and are anticipated to drive substantial brand awareness and sales growth, although initial investments will weigh on operating margins in the near term.
Margin resilience and discounting strategy: Despite increasing its membership discount, RH believes its elevated product mix and operational efficiencies will support full-year non-GAAP margin targets. Management noted that margin improvement is expected as product assortment optimizes and as European galleries scale, but acknowledged ongoing promotional intensity and macro volatility as risks.
Tariff and supply chain adjustments: The company continues to shift sourcing out of China and work closely with vendor partners to absorb tariff costs. Management warned of near-term revenue timing disruptions and supply chain unpredictability, but expressed confidence that these challenges are being addressed through diversified sourcing and inventory management.
Going forward, the StockStory team will focus on (1) the pace and performance of new flagship gallery openings in Europe, (2) how RH manages product margins and inventory in the face of elevated promotions and tariffs, and (3) whether the shift in membership discount strategy drives meaningful incremental demand without eroding brand positioning. Progress on monetizing real estate assets and supply chain diversification will also be important indicators.
RH currently trades at a forward P/E ratio of 15.8×. Should you double down or take your chips? Find out in our full research report (it's free).
Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
CVS Health Corporation (CVS) Outpaces Broader Market with Strong 2025 Rally
CVS Health Corporation (NYSE:CVS) is one of the Best Dividend Stocks of 2025. A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products. Following a challenging year in 2024, CVS Health Corporation (NYSE:CVS) appears to be making progress toward a recovery. The company remains committed to becoming the most trusted healthcare provider in the United States by delivering improved care, value, and service through its integrated and industry-leading operations. The stock has surged by over 50% since the start of 2025. With a strong focus on customer needs, CVS Health Corporation (NYSE:CVS) reported positive results across its Health Care Benefits, Health Services, and Pharmacy and Consumer Wellness segments. The company continues working toward its goal of building a healthier future for the 185 million individuals it serves. CVS Health Corporation (NYSE:CVS) also updated its full-year 2025 guidance for GAAP diluted earnings per share, adjusted earnings per share, and operating cash flow to reflect strong performance across all business areas. However, the company is maintaining a cautious outlook for the rest of the year due to ongoing elevated cost trends and potential broader economic challenges. CVS Health Corporation (NYSE:CVS) has paid regular dividends to shareholders since 1997. The company's quarterly dividend comes in at $0.665 per share for a dividend yield of 3.90%, as of June 26. While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Sign in to access your portfolio

Business Insider
an hour ago
- Business Insider
"We can turn Africa into a 'heaven' in the next five years" — Dangote
Africa's richest man, Aliko Dangote, has urged Africans to adopt bold thinking and a long-term mindset, asserting that the continent could be transformed into a 'heaven' within just five years. Aliko Dangote, Africa's richest man, advocates for bold thinking and long-term vision to transform the continent within five years. Dangote emphasized that Africans must believe in their potential to make the continent productive and growth-focused. He has spearheaded major investments, including the $20 billion Dangote Refinery in Lagos, the world's largest single-train oil refinery. Africa's richest man, Aliko Dangote, has urged Africans to adopt bold thinking and a long-term mindset, asserting that the continent could be transformed into a 'heaven' within just five years. He made the remarks on Friday while speaking at the 32nd Annual Meeting of the African Export-Import Bank (Afreximbank). 'We can actually turn Africa into a heaven in the next five years. It doesn't take time. Like I keep saying: You need to think big, and then you grow big,' Dangote stated. 'We African champions should know that we are the only people who can make Africa great. Nobody will do that for us. So, as such, we need to make sure that we concentrate. We believe in our own continent. The job of people like us is not about amassing wealth. It's about creating wealth," he said. Africa's foremost industrialist has long championed investments in the continent's development. His commitment recently drew praise from the Nigerian government for prioritizing national advancement over the allure of tech windfalls. Rather than betting on global giants like Amazon, Microsoft, or Google, investments that could have boosted his net worth to $120 billion, Dangote chose instead to build the world's largest single-train oil refinery in Lagos. Reshaping Africa's energy future Valued at $20 billion, the Dangote Refinery is now Africa's biggest and a transformative force in the region's energy sector. Although delayed for several years, the refinery officially began production of diesel, naphtha, and jet fuel in January last year, followed by petrol production in September. The massive facility surpasses the capacity of Europe's 10 largest refineries. According to the Organisation of the Petroleum Exporting Countries (OPEC), Dangote's oil push in Nigeria is already starting to disrupt the European oil market. Economists suggest that the Dangote refinery could potentially end the long-standing gasoline trade from Europe to Africa, which is valued at $17 billion annually. Earlier this year, Aliko Dangote projected that his conglomerate is on track to generate $30 billion in total revenue next year, despite growing concerns among global businesses about the potential impact of U.S. President Donald Trump's trade tariffs.


Business Wire
4 hours ago
- Business Wire
WST截止日期:Rosen Law Firm敦促損失超過10萬美元的West Pharmaceutical Services, Inc. (NYSE: WST)股東與法律事務所聯絡以瞭解有關其權利的資訊
紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球投資人權益法律事務所Rosen Law Firm提醒投資人,一名股東代表在2023年2月16日至2025年2月12日期間購買West Pharmaceutical Services, Inc. (NYSE: WST)證券的投資人提起了集體訴訟。West將自身描述為一家「專注於注射藥物包裝元件、密封解決方案及輸送系統的醫療用品公司」。 如欲瞭解更多資訊,請遞交 表格 、向Phillip Kim律師 寄送電子郵件 ,或致電866-767-3653聯絡我們。 指控內容:Rosen Law Firm正在調查對West Pharmaceutical Services, Inc. (NYSE: WST)在其業務營運方面誤導投資人的指控。 起訴書指稱,在整個集體訴訟期內,被告做出了虛假和誤導性陳述及/或未揭露:(1)儘管聲稱對客戶需求有清晰預判,並將業務阻力歸咎於COVID相關產品的臨時性去庫存,但West實際上在其高利潤率的高價值產品(HVP)組合中持續經歷著顯著的去庫存現象;(2) West的SmartDose裝置雖被標榜為高利潤率的成長型產品,但由於營運效率不彰,對West的利潤率造成了嚴重稀釋;(3)這些利潤率壓力引發了高昂重整活動的風險,包括West退出與長期客戶簽署的持續血糖監測(CGM)合約;以及(4)由於上述原因,被告關於West的業務、營運和前景的正面陳述具有重大誤導性和/或缺乏合理依據。訴訟稱,當市場瞭解真實詳情後,投資人蒙受了損失。 現在怎麼辦:您可能有資格參與針對West Pharmaceutical Services, Inc.的集體訴訟。如果有股東希望擔任該集體訴訟的原告代表,則必須在2025年7月7日之前向法院提出申請。原告代表是指代表其他集體訴訟成員主導訴訟的當事人代表。您無需參與此案即有資格獲得追償。如果您選擇不採取任何行動,您也可以保持缺席集體訴訟成員的身分。如欲瞭解更多資訊,請點選 此處 。 所有代理均為勝訴後取酬。股東無需支付任何費用或開支。 關於Rosen Law Firm:與Rosen Law Firm不同,一些就此等事宜發表公告的法律事務所並不會實際提起證券集體訴訟。身為股東權益訴訟領域公認的領導者, Rosen Law Firm 一直致力於協助股東挽回損失、改善公司治理結構,並追究公司高階主管的違法行為責任。自成立以來,Rosen Law Firm已經為股東挽回了超過10億美元的損失。 請在LinkedIn: 、Twitter: 或Facebook: 上關注我們,以瞭解最新情況。 律師廣告。先前案例不保證可獲致類似結果。 免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。